In conclusion, while the majority of the evidence suggests a negative association between CD44 expression and chemotherapy outcomes, the complexity of cancer heterogeneity, treatment variations, and diverse outcome measures warrant cautious interpretation. This evidence concerns the gene CD44 and cancer.